Oncology · Medical Literature
Transdermal Estradiol Patches in Prostate Cancer
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 517-518, July 30, 2026.
Clinical relevance
In men with locally advanced (M0, N0/N+) prostate cancer requiring androgen-deprivation therapy, is transdermal estradiol (tE2) noninferior to injectable LHRH agonists for 3-year metastasis-free survival? __SNAPSHOT__ {"studyDesign":"Phase 3, open-label, randomized noninferiority trial (combined PATCH [NCT00303784] and STAMPEDE-1 [NCT00268476] programs)","setting":"75 centers across the United Kingdom; recruitment 2007–2022","sampleSize":"n = 1,360 (tE2: n = 721; LHRH agonists: n = 639)","population":"Men with locally advanced, non-metastatic prostate cancer (M0, N0 or N+); median age 72 years (IQR 68–77); 85% T3 tumor stage; 65% N0 nodal stage; median PSA approximately 24 ng/mL","intervention":"Transdermal estradiol patches delivering 100 µg of estradiol per 24 hours; initial dose four patches changed twice weekly, titrated to three patches twice weekly once castrate testosterone levels achieved","comparator":"Injectable LHRH agonists administered subcutaneously every 4 or 12 weeks; short-course bicalutamide or flutamide permitted for up to 8 weeks","primaryOutcome":"3-year metastasis-free survival (MFS); noninferiority margin of 4 percentage points corresponding to a target hazard ratio of 1.31","followUp":"Minimum 3 years for primary endpoint; 5-year overall survival data also reported","fundingSource":"Non-profit government: Cancer Research UK and UK Research Institute Medical Research Council; no industry funding reported"}
Key findings
PRIMARY OUTCOME: 3-year MFS was 87.1% with tE2 versus 85.9% with LHRH agonists (HR for confirmed metastasis or death 0.96; upper limit of one-sided 95% CI 1.11), meeting the prespecified noninferiority criterion (upper CI limit < 1.31). The absolute difference in 3-year MFS was +1.2 percentage points in favor of tE2 (calculated). SECONDARY OUTCOMES: 5-year overall survival was 81.1% with tE2 versus 79.2% with LHRH agonists (HR for death 0.90; 95% CI 0.75–1.07); this difference was not statistically significant, and superiority was not established. Castrate testosterone levels (<1.7 nmol/L) were achieved and sustained during the first year in approximately 85% of patients in each group among those continuing assigned treatment. SAFETY: Hot flashes occurred in 44% of tE2 patients versus 89% of LHRH agonist patients (grade ≥2: 8% vs. 37%), representing a clinically meaningful reduction. Gynecomastia occurred in 85% of tE2 patients versus 42% of LHRH agonist patients (grade ≥2: 37% vs. 9%), representing a clinically important increase. Prior phase 2 data from the PATCH program showed no significant difference in cardiovascular event rates between arms (HR 1.11; 95% CI 0.80–1.53; p = 0.54), and improved bone mineral density with tE2 versus LHRH agonists. No NNT/NNH for efficacy endpoints is calculable from abstract-level data alone; NNH for any-grade gynecomastia is approximately 2.3 (calculated from 85% vs. 42% event rates).
Practice implications
IMPORTANT NOTE: Only the abstract of the primary trial (Langley et al., NEJM, April 2026) is available; the user-cited citation (Vol. 395, Issue 5, pp. 517–518, July 30, 2026) refers to post-publication correspondence letters (Sears & Schuller; Grossmann & Russell; reply by Langley, Gilbert & Nankivell), which do not contain an abstract. This summary is therefore based on abstract-level data from the primary article to which those letters respond. WHAT THE STUDY ESTABLISHED: tE2 patches are noninferior to LHRH agonists for 3-year MFS in men with locally advanced, non-metastatic prostate cancer, with equivalent rates of testosterone suppression. The study offers the first phase 3 evidence supporting tE2 as a legitimate ADT alternative with a distinct toxicity profile—substantially fewer hot flashes and less bone loss, but substantially more gynecomastia. WHAT THE STUDY DID NOT ESTABLISH: Superiority for any efficacy endpoint was not demonstrated. Overall survival benefit remains uncertain (HR 0.90; 95% CI 0.75–1.07). Data on combination with androgen receptor pathway inhibitors (e.g., enzalutamide, abiraterone) are limited, and safety of such combinations is not established. Results for men with metastatic (M1) disease are reported separately and are not yet published. GENERALIZABILITY: The trial enrolled exclusively in the UK, limiting direct generalizability to health systems where radiotherapy practice, concomitant therapy protocols, and patient demographics differ. The 15-year enrollment window (2007–2022) means that many patients were treated before contemporary intensified ADT backbones (e.g., ARSI combinations) were standard. REGULATORY STATUS: tE2 patches are not currently licensed for prostate cancer in the UK or elsewhere; prescribing remains off-label. Practice change requires regulatory action and shared decision-making discussions about the gynecomastia/hot-flash trade-off. __LIMITATIONS__ Open-label design: No blinding was feasible, introducing potential ascertainment bias for subjective adverse events (hot flashes, gynecomastia).,15-year enrollment window (2007–2022): Standard of care evolved substantially during the trial, including the introduction of prostate radiotherapy as standard for M0 disease and widespread adoption of ARSI combination therapy, potentially confounding outcomes and limiting contemporary applicability.,Surrogate primary endpoint: 3-year metastasis-free survival is an intermediate endpoint; overall survival benefit was not demonstrated (HR 0.90; 95% CI 0.75–1.07).,Single-country trial: All 75 centers were in the UK; generalizability to other health systems, ethnic populations, and prescribing environments is uncertain.,Asymmetric randomization: tE2 arm (n=721) was larger than control arm (n=639), which may reflect adaptive platform trial features but warrants scrutiny for potential allocation imbalance.,Regulatory gap: tE2 is not licensed for prostate cancer; the patch formulation used is approved for menopausal HRT in women, creating off-label prescribing, dosing, and monitoring challenges in clinical practice.,Metastatic cohort results pending: M1 patients were enrolled in a parallel cohort; those data are not yet reported, limiting conclusions to the locally advanced, non-metastatic population.,ARSI combination safety not established: The interaction between tE2 and androgen receptor signaling inhibitors was not prospectively evaluated in this trial.,Only abstract available for this summary: Full methods, pre-specified subgroup analyses, adherence data, crossover rates, and patient-reported outcome details were not accessible. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ In men with locally advanced, non-metastatic prostate cancer, transdermal estradiol patches (100 µg/24 h) achieved 3-year metastasis-free survival noninferior to LHRH agonists (87.1% vs. 85.9%; HR 0.96), with equivalent testosterone suppression and a meaningfully lower rate of hot flashes. However, gynecomastia was substantially more common with tE2 (85% vs. 42%), tE2 remains off-label for this indication, and data on combination with contemporary ARSI-based regimens are lacking, so patient selection and shared decision-making regarding the hot flash/gynecomastia trade-off are essential before adoption.